Receptos to Present at UBS Global Healthcare Conference
14 Maggio 2015 - 2:00PM
Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company
developing therapeutic candidates for the treatment of immune and
metabolic diseases, today announced that management will be
presenting at the UBS Global Healthcare Conference at the Sheraton
New York Times Square Hotel in New York City. The presentation is
scheduled for Wednesday, May 20th at 12:00pm Eastern time.
About Receptos
Receptos is a biopharmaceutical company developing
therapeutic candidates for the treatment of immune and metabolic
diseases. The Company's lead program, ozanimod (formerly RPC1063),
is a sphingosine 1-phosphate 1 and 5 receptor small molecule
modulator in development for immune indications including relapsing
multiple sclerosis and inflammatory bowel disease. Patents
supporting RPC1063 were exclusively licensed to
Receptos from The Scripps Research
Institute (TSRI). The Company is also developing RPC4046,
an anti-interleukin-13 (IL-13) antibody for eosinophilic
esophagitis (EoE), an allergic/immune-mediated orphan disease.
CONTACT: Media and Investor Contact:
Graham K. Cooper
Chief Financial Officer, Receptos
(858) 652-5708
gcooper@receptos.com
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Lug 2024 a Ago 2024
Grafico Azioni RECEPTOS, INC. (NASDAQ:RCPT)
Storico
Da Ago 2023 a Ago 2024
Notizie in Tempo Reale relative a (MM) (NASDAQ): 0 articoli recenti
Più Articoli Notizie